Journal article
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease
Abstract
AIMS: The COMPASS trial demonstrated that the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease or peripheral artery disease by 24% during a mean follow-up of 23 months. We explored whether this effect varies by sex.
METHODS AND RESULTS: The effects were examined in women and men …
Authors
Liang Y; Zhu J; Liu L; Anand SS; Connolly SJ; Bosch J; Guzik TJ; O’Donnell M; Dagenais GR; Fox KA
Journal
Cardiovascular Research, Vol. 117, No. 3, pp. 942–949
Publisher
Oxford University Press (OUP)
Publication Date
February 22, 2021
DOI
10.1093/cvr/cvaa100
ISSN
0008-6363
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AgedAged, 80 and overAspirinComorbidityCoronary Artery DiseaseDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFactor Xa InhibitorsFemaleHealth Status DisparitiesHemorrhageHumansMaleMiddle AgedMyocardial InfarctionPeripheral Arterial DiseasePlatelet Aggregation InhibitorsRisk AssessmentRisk FactorsRivaroxabanSex FactorsStrokeTime FactorsTreatment Outcome